i2o 120
Alternative Names: i2o-120; I2o120Latest Information Update: 15 Jan 2024
At a glance
- Originator i2O Therapeutics
- Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 31 Aug 2023 Preclinical trials in Non-alcoholic steatohepatitis in USA (unspecified route) (i2o Therapeutics pipeline, August 2023)
- 31 Aug 2023 Preclinical trials in Obesity in USA (unspecified route) (i2o Therapeutics pipeline, August 2023)
- 31 Aug 2023 Preclinical trials in Type 2 diabetes mellitus in USA (unspecified route) (i2o Therapeutics pipeline, August 2023)